These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2588762)

  • 1. Clinical chronopharmacology of oral nitrates.
    Lemmer B; Scheidel B; Stenzhorn G; Blume H; Lenhard G; Grether D; Renczes J; Becker HJ
    Z Kardiol; 1989; 78 Suppl 2():61-3; discussion 64-7. PubMed ID: 2588762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronopharmacology of oral nitrates in healthy subjects.
    Scheidel B; Lemmer B
    Chronobiol Int; 1991; 8(5):409-19. PubMed ID: 1818789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.
    Lemmer B; Scheidel B; Blume H; Becker HJ
    Eur J Clin Pharmacol; 1991; 40(1):71-5. PubMed ID: 2060550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
    Keller-Stanislawski B; Marschner JP; Rietbrock N
    Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the initial hemodynamic effects of immediate-release versus sustained-release isosorbide-5-mononitrate following single oral doses.
    Trenk D; Hinder M; Stengele E; Bonn R; Jähnchen E
    J Clin Pharmacol; 2000 Feb; 40(2):168-76. PubMed ID: 10664923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
    Arthur RM; Mehmel H
    Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
    Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
    Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative hemodynamic study of IS-5-MN and ISDN in man--which are equieffective doses?
    Vogt A; Bernhardt S; Schwarck H; Stroh E; Kreuzer H
    Z Kardiol; 1983; 72 Suppl 3():182-4. PubMed ID: 6666220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
    Schaumann W
    Int J Clin Pharmacol Ther Toxicol; 1989 Sep; 27(9):445-53. PubMed ID: 2681004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
    Laufen H; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics and pharmacodynamics of one-week monotherapy with IS-5-N s.r. 50 or 100 mg, ISDN s.r. 120 mg or IS-5-N 2 x 20 mg in coronary heart disease patients.
    Jansen W; Prenzel R; Düring C; Rappert B; Geppert R
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):504-5. PubMed ID: 1490808
    [No Abstract]   [Full Text] [Related]  

  • 15. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronopharmacodynamics of delayed-action cardiac glycosides and nitrates].
    Zaslavskaia RM; Vilkovyskiĭ FA; Goncharov LF
    Kardiologiia; 1990 Dec; 30(12):11-3. PubMed ID: 2097386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Bonn R; Fritschi E; Jaeger H
    Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Theodor R; Pabst G; Bonn R; Fritschi E; Jaeger H
    J Clin Pharmacol; 1992 Jun; 32(6):553-7. PubMed ID: 1634643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained hemodynamic and antianginal effects of high dose oral isosorbide dinitrate.
    Aronow S
    Nouv Presse Med; 1980 Sep; 9(34 Suppl):2483-6. PubMed ID: 7422537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
    Johnson KI; Gladigau V; Schnelle K
    Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.